Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
NCT04104672 is registered in ClinicalTrials.gov with Arcus Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
- Lead sponsor
- Arcus Biosciences, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 6, 2019
- Completion date
- July 21, 2026
- Enrollment
- 196 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
advanced pancreatic cancer